Argenx reports full year 2024 financial results and provides fourth quarter business update

$737 million in fourth quarter and $2.2 billion in full year global product net sales received positive chmp recommendation for vyvgart pre-filled syringe for gmg, enabling launch in the eu; fda pdufa (gmg and cidp) on track for april 10 10 phase 3 and 10 phase 2 studies across pipeline ongoing in 2025, positioning for next wave of growth recognized one-time tax benefit of $725 million related to previously unrecognized deferred tax assets management to host conference call today at 2:30 pm cet (8:30 am et) february 27, 2025 7:00 am cet amsterdam, the netherlands – argenx se (euronext & nasdaq: argx), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today reported financial results for the full year 2024 and provided a fourth quarter business update. "in 2024, we significantly expanded our global patient reach with vyvgart, surpassing 10,000 patients across three indications,” said tim van hauwermeiren, chief executive officer of argenx.
ARGX Ratings Summary
ARGX Quant Ranking